

### Analyst

Tanushree Jain 612 8224 2849

### Authorisation

TS Lim 612 8224 2810

# Pharmaxis Ltd. (PXS)

## FY19 Audited Results - No material change

### Recommendation

**Buy** (unchanged)

Price

**\$0.195**

Valuation

**\$0.57** (unchanged)

Risk

**Speculative**

### GICS Sector

Pharmaceuticals & Biotechnology

### Expected Return

Capital growth	<b>192.3%</b>
Dividend yield	<b>0.0%</b>
Total expected return	<b>192.3%</b>

### Company Data & Ratios

Enterprise value	<b>\$52.9m</b>
Market cap	<b>\$76.9m</b>
Issued capital	<b>394.3m</b>
Free float	<b>98.7%</b>
Avg. daily val. (52wk)	<b>\$70,625</b>
12 month price range	<b>\$0.18- \$0.33</b>

### Price Performance

	(1m)	(3m)	(12m)
Price (A\$)	0.24	0.28	0.31
Absolute (%)	-18.75	-29.09	-36.07
Rel market (%)	-14.52	-30.74	-38.27

### Absolute Price



SOURCE: IRESS

BELL POTTER SECURITIES LIMITED  
ABN 25 006 390 7721  
AFSL 243480

### Not much new information in the audited financials

There was no material change in the audited FY19 results from the unaudited results as per PXS' quarterly update released last month. Timelines for key catalysts remain unchanged since the last update. Partner Boehringer Ingelheim completed the Phase 2A trial for NASH in June'19 and results from this are expected in early 4QCY19. We understand the results will also be accompanied by a status update for the program from BI. Therefore if BI based on results confirms that it plans to move the drug BI 1467335 ahead into Phase 2b trials for NASH, it will be a huge vote of confidence from them and de-risk the asset in our view. Results from the other ongoing BI trial in Diabetic Retinopathy is expected in 1HCY20 (expected completion of trial in Jan'20).

PXS expects Chiesi to complete the requirements as per FDA's Complete Response Letter i.e. revise Bronchitol product packaging and user instructions and the Human Factor Study to show that the revised instructions enable doctors to properly administer the mannitol tolerance test by end of CY19. PXS expects FDA approval decision in 1QCY20, with potential milestone (US\$10m) from Chiesi in 2QCY20.

Completion of commercial process for LOXL-2 asset is expected by end CY19. We continue to believe that this asset being one of the true anti-fibrotic mechanisms in play has good partnering potential. A Phase 2 trial for NASH with LOXL-2 will require considerable funding **and in the absolute bear case scenario**, if PXS is unable to partner the asset based on Phase 1 data and tox studies, we believe PXS is likely to be prudent to use its cash reserves to move other pipeline assets (namely its LOX assets targeting myelofibrosis and scarring) into Phase 2 (as they will be relatively cheaper, with faster path to market and commercially valuable), rather than funding a LOXL-2 Phase 2 itself (grants could be pursued to progress LOXL-2).

Proforma cash of \$37m, provide ~22 months runway ahead of boost expected through licensing deal for LOXL-2 and milestone from Chiesi.

### Retain Buy (speculative) and Valuation of \$0.57

Given there was not much new information in the audited financials vs. the unaudited numbers released in July'19, we have not made any changes to our forward forecasts. Our valuation for PXS remains unchanged at A\$0.57/sh. We retain Buy (Spec).

### Earnings Forecast

Year end 30th June	2018A	2019A	2020E	2021E	2022E
Revenue (A\$m)	50.2	12.2	32.0	20.1	16.1
EBITDA (A\$m)	11.5	-15.7	5.6	-6.2	-7.7
NPAT (reported) (A\$m)	6.4	-20.1	2.8	-8.8	-10.4
NPAT (normalised) (A\$m)	7.6	-19.0	4.0	-7.5	-9.1
EPS (reported) (cps)	2.0	-5.1	0.7	-2.2	-2.6
EPS (adjusted) (cps)	2.4	-4.8	1.0	-1.9	-2.3
EPS growth (%)	NM	N/A	NM	N/A	N/A
PER (x)	8.2	N/A	19.5	N/A	N/A
EV/EBITDA (x)	4.6	-3.4	9.5	-8.5	-6.9
Dividend (cps)	0.0	0.0	0.0	0.0	0.0
Yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Franking (%)	N/A	N/A	N/A	N/A	N/A
ROE (%)	68.5%	NM	21.1%	NM	NM

NOTE: REVENUE INCLUDES R&D TAX INCENTIVE, MILESTONES FROM BI DEAL AND CHIESI DEAL AND FY20/21 REVENUE INCLUDES RISK ADJUSTED UPFRONT AND MILESTONES FROM LICENSING DEAL FOR LOXL-2. SOURCE: BELL POTTER SECURITIES ESTIMATES

DISCLAIMER: THIS REPORT MUST BE READ WITH THE DISCLAIMER ON PAGE 10 THAT FORMS PART OF IT.  
DISCLOSURE: BELL POTTER SECURITIES ACTED AS JOINT LEAD MANAGER FOR THE \$24M PLACEMENT IN AUGUST 2018 AND RECEIVED FEES FOR THAT SERVICE.

# FY19 Results – No material change from unaudited results released in July

## FY19 – Result Summary

There was no material change in the audited FY19 results released on the ASX from the unaudited results as per PXS' quarterly update released at the end of July'19. The EPS/share numbers have now been updated. A summary of the reported FY19 result is shown in the Table below:

Table 1 - FY19 result summary					
	Result vs PCP			Result vs Forecast	
	FY18A	FY19A	% change	FY19E	Variance (%)
<b>Revenues</b>	<b>50.2</b>	<b>12.2</b>	<b>-76%</b>	<b>12.2</b>	<b>0%</b>
<b>Total operating costs</b>	<b>38.7</b>	<b>27.8</b>	<b>-28%</b>	<b>27.8</b>	<b>0%</b>
<b>EBITDA</b>	<b>11.5</b>	<b>-15.7</b>	<b>NM</b>	<b>-15.7</b>	<b>0%</b>
Depreciation and Amortisation	-3.1	-2.6	-16%	-2.6	0%
<b>EBIT</b>	<b>8.4</b>	<b>-18.3</b>	<b>NM</b>	<b>-18.3</b>	<b>0%</b>
Net Interest Income/(expense)	0.0	0.4	NM	0.4	0%
Other Income/(expense)	-0.8	-1.1	-37%	-1.1	0%
Pretax Income (Loss)	7.6	-19.0	NM	-19.0	0%
<b>Net Income (Loss) after tax - normalised</b>	<b>7.6</b>	<b>-19.0</b>	<b>NM</b>	<b>-19.0</b>	<b>0%</b>
Diluted EPS/Share (cents)	2.38	-4.84	NM	-5.06	-4%
<i>One off items</i>	-1.20	-1.08	-10%	-1.08	0%
<b>Reported Net Income (loss)</b>	<b>6.4</b>	<b>-20.1</b>	<b>NM</b>	<b>-20.1</b>	<b>0%</b>
Reported Diluted EPS/sh (cents)	2.01	-5.12	NM	-5.35	-4%

SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES

**Strong cash position:** PXS' cash reserves are A\$31.1m. Borrowings are just lease liabilities and hence included in our cash burn assumptions. An R&D tax rebate of \$6m is expected to be received in 2HCY19. This should provide ~22 months cash runway ahead of further boost expected through a licensing deal for LOXL-2 asset in 2HCY19 and a US\$10m milestone payment from Chiesi in 2QCY20, following US approval of Bronchitol (milestone is triggered once product is shipped to Chiesi for sale).

## No change to Earnings or Valuation

Given there was not much new information in the audited financials vs. the unaudited numbers released at end of July'19, we have not made any changes to our forward forecasts.

Our valuation for PXS remains unchanged at A\$0.57/sh. **We retain our Buy (Speculative) recommendation.**

Our DCF valuation model is based on a WACC of 16.0% and a terminal growth rate of 1%.

Table 2 - Summary of Valuation	
Forecasts	Base case
Enterprise value from DCF (AUDm)	211.8
Add: Reported Cash (AUDm)	31.1
Less: Current Debt	7.2
Equity value (AUDm)	235.7
Total diluted shares (million)	414.4
<b>Value per share (AUD)</b>	<b>\$0.57</b>
Current Share price (AUD)	\$0.20
Expected Capital Growth	192.3%

SOURCE: BELL POTTER SECURITIES ESTIMATES

Table 3 - PXS Sum-of-parts DCF Valuation Summary

Asset	Probability adjusted NPV (A\$m)	Value per share (A\$)	% Mix	Probability of success/Risk adjustment	Current Phase
Bronchitol and Aridol	\$19	\$0.05	8.1%	Aridol - Canada (100%), Bronchitol - US (85%)	Marketed (Ex-Canada) and for Bronchitol (Ex-US and Canada)
New Drug Development	\$229	\$0.55	97.1%	BI_1467335 (NASH, DR - 23.5%), LOXL-2 (NASH -22.0%)	BI_1467335 (Phase 2A) and LOXL-2 (Phase 1 complete)
Corporate/Non-Allocated	(\$36)	-\$0.09	-15.3%	NA	NA
Reported Cash	\$31	\$0.08	13.2%	NA	NA
Reported Debt	(\$7)	-\$0.02	-3.0%	NA	NA
<b>Equity Value</b>	<b>\$235.7</b>	<b>\$0.57</b>	<b>100.0%</b>		

SOURCE: BELL POTTER SECURITIES ESTIMATES

Table 4 – PXS- Key assumptions used in New Drug Development segment

Asset	Indication	Stage	Partnering Status	First Fiscal Year of sales (Est.)	Peak Market share	Peak Global Sales (US\$m)	Probability of success
BI_1467335	NASH - F2/F3 fibrosis stage	Phase 2A	Boehringer Ingelheim	2027	5% (US), (3.5% ROW)	\$1,962	23.5%
BI_1467335	Diabetic Retinopathy (DR)	Phase 2A	Boehringer Ingelheim	2027	10.0%	\$813	23.5%
LOXL-2	NASH - F3/F4 fibrosis stage	Phase 1 complete	Will look to partner	2029	5% (US), (3.5% ROW)	\$1,448	22.0%

GLOBAL PEAK SALES ARE PRE-RISK ADJUSTMENT AND ROYALTIES. SOURCE: BELL POTTER SECURITIES ESTIMATES

Table 5 – Deal Assumptions for Key Drug Development Pipeline Assets

Asset	Indication	Stage at Licensing	Licensee	Fiscal Year Timing of deal (Est.)	Total Deal Value in USDm (upfront plus milestones)	Upfront (USDm)	Other developmental & regulatory Milestones (USDm)	Commercial Milestones Est (USDm)	Royalty Rate (%)	PXS's share
BI_1467335	NASH and Diabetic Retinopathy	Phase 1	Boehringer Ingelheim	2015	645	33	462	150	11.0%	100.0%
LOXL-2	NASH and a second indication (potentially IPF)	Phase 1 complete	TBC	2020	700	50	470	180	11.0%	83.0%

NOTE: ROYALTIES ARE LIKELY TO BE TIERED. WE ASSUME A FLAT RATE FOR NOW. FOR LOXL-2 DEAL PXS AND ITS PARTNER SYNAIRGEN WILL SHARE THE DEAL VALUE IN 83:17 RATIO. THE BI DEAL VALUE INCLUDES OUR ESTIMATES ABOUT POTENTIAL UNDISCLOSED COMMERCIAL MILESTONES WHICH ARE PART OF THE DEAL AND HENCE MAY BE CONSERVATIVE. THE BI DEAL IS IN EUROS, WE HAVE CONVERTED IT TO USD AT CURRENT EXCHANGE RATES. SOURCE: BELL POTTER SECURITIES ESTIMATES

## Upside Risk to our valuation

- Clinical success will allow for increased probability of success:** We currently assign a 23.5% probability of success (of reaching the market) to BI\_1467335, given that it's currently in a Phase 2A trial, for both NASH and DR. We envisage that completion of the trials with positive results and subsequent advancement of BI\_1467335 into Phase 2B trials (BPe CY20) will allow us to assign a higher probability of success and therefore will lead to material upgrades in our numbers.

Similarly, we currently assign a 22.0% probability of success (of reaching the market) to LOXL-2 in NASH, following the successful completion of its Phase 1 trial. We envisage that subsequent advancement of LOXL-2 into Phase 2A trials will allow us to assign a higher POS and therefore will lead to material upgrades in our numbers.

- Conservative assumptions for BI\_1467335 in absence of Phase 2 clinical data:** Our market penetration & pricing assumptions, are all based on the premise that BI\_1467335 will be behind a few years to other NASH approaches such as Allergan's CCR2/CCR5 antagonist and Gilead's selonsertib. Our base assumption at this stage is that BI\_1467335 shows at least equivalent efficacy to these assets, with a better safety profile, with the advantage potentially to be used both as a monotherapy and in combination, in the moderate-severe fibrosis stage NASH population, with one or more approved assets by that stage. In the absence of Phase 2 clinical data we are conservative in our assumptions at this stage.
- Conservative assumptions for LOXL-2 to start with in absence of Phase 2 clinical data:** Our market penetration & pricing assumptions and deal size assumptions, are all based on the premise that LOXL-2 will be behind several years to other drugs targeting NASH to get to market. At that stage we expect the drug is more likely than not to be

used as an add on therapy with existing standard of care by then to improve efficacy, likely in the more severe end of the fibrosis stage spectrum of NASH. However, given the scarcity of anti-fibrotic assets in development for NASH, we expect both partnering interest and deal size for the LOXL-2 asset with its novel mechanism of action (MoA) to be in line with other high value deals in this space recently. In the absence of Phase 2 clinical data from LOXL-2 we are conservative in our assumptions at this stage including our assumptions for the deal size.

- **We do not model royalty revenue from a second indication (likely IPF) for LOXL-2 presently:** At this stage in our valuation, we do not include a market revenue model for LOXL-2 for Idiopathic Pulmonary Fibrosis (IPF) as a potential secondary indication and therefore do not model royalty revenue as a percentage of net sales from this indication to PXS. Confirmation of IPF as a second indication by PXS' future partner and progress of this into Phase 2 clinical trials is likely to considerably increase the market opportunity for this asset, in which case it's likely to be a source of considerable upside to our valuation in future.
- **No sales milestones from LOXL-2 deal included in our model:** At this stage we do not model PXS' share of the assumed US\$180m sales milestones from a potential LOXL-2 deal in our model. We intend to include it in our model once a LOXL-2 deal is inked by PXS, in which case it's likely to be a source of upside to our valuation.
- **No value assigned for other early stage pipeline assets:** We also do not include any value for PXS' early stage assets namely 2 LOX inhibitors (systemic and topical). The LOX inhibitor program is developing a drug which broadly inhibits all the LOX family of enzymes, which has potential anti-fibrotic application in scarring (a topical formulation) and other severe fibrotic indications including some cancers (a systemic formulation).

PXS has initiated a Phase 1 trial in healthy volunteers with its LOX systemic asset in Feb'19. The SAD (single ascending dose) part of this study was completed in June'19 and the company will conduct the second MAD (multiple ascending dose) in 2HCY19. PXS has had positive results from its LOX systemic asset in myelofibrosis and pancreatic cancer in preclinical models and has completed 3 month toxicology studies while running the currently ongoing Phase 1 trial in healthy volunteers. Longer term tox studies (6 months) are also being carried out in parallel for the compound. PXS intends to start a clinical study in myelofibrosis and/or pancreatic cancer patients in 1HCY20. Preclinical development is continuing for the topical asset, with PXS targeting early 2020 to start a Phase 1 trial in healthy volunteers with scarring.

PXS believes that the above two assets may have higher potential and value add if developed to Phase 2A or 2B before partnering, vs. the strategy with its later stage assets targeting NASH which it looked to partner at or after Phase 1. Progress of these two assets into Phase 2 trials in future is likely to be a source of upside to our valuation.

- **We model limited markets for Bronchitol and risk adjust the US opportunity:** For Bronchitol, we model the existing markets of Australia, Western Europe including Italy, Eastern Europe and Russia and now also model US, following the recent positive recommendation in support of approval by the FDA advisory committee and CRL received from the FDA. PXS' US partner Chiesi is responsible for its commercialisation. Should Bronchitol get approved and launch in US, PXS will receive a US\$10m milestone from Chiesi, additional US\$15m sales milestones and a mid to high teen percentage of royalties on net sales. At this stage we assign US sales and the launch milestone from Chiesi an 85% probability of success, given FDA approval is yet to be granted, although the likelihood based on the CRL is high. FDA approval and launch of Bronchitol in the US therefore will be an upside to our valuation for PXS. We also do not model the US\$15m sales milestone receivable from Chiesi on meeting certain undisclosed sales thresholds at this stage, which would represent an upside.

- **We model limited markets for Aridol:** For Aridol, we model the existing markets of Australia, Europe and South Korea and now also model US where the company relaunched Aridol in Dec'18 following FDA approval of its manufacturing facility. We also model revenue from Canada, given Aridol received approval in June 2019. PXS expects launch in 2HCY19 in Canada.
- **Small contribution from Bronchitol and Aridol segment in our valuation:** With the addition of the US opportunity for Bronchitol in our model, we now expect the Bronchitol and Aridol segment to transition to profitability over the next 1-2 years. Excluding the US opportunity, we believe Russia for Bronchitol and Canada for Aridol may surprise us on the upside, however at this stage we choose to be conservative till we see increasing traction in Russia for Bronchitol after obtaining wider reimbursement and launch in Canada for Aridol.

## Pharmaxis Ltd. (PXS)

### COMPANY DESCRIPTION

Pharmaxis, is a biopharmaceutical company focused on the development of drugs for inflammatory and fibrotic diseases. Its lead assets Phase 2 SSAO/VAP-1 inhibitor BI\_1467335 partnered in a multi-million dollar deal with Boehringer Ingelheim and currently unpartnered Phase 1 LOXL-2 inhibitors are targeting Non-alcoholic Steatohepatitis (NASH), a multibillion dollar market, estimated to grow to be ~US\$20bn-US\$35bn. The drugs while not first-in-class, have the potential to be best-in-class and be useful in other fibrotic diseases and we forecast both to be blockbusters (i.e. have over US\$1bn in peak sales). NASH market is expected to grow with rise in obesity and surpass HCV as the leading cause of liver transplant by 2020. There are currently no approved drugs which make the market largely untapped and underserved. The multifactorial aspect of NASH and future treatments likely to be a combination of therapies ensures that companies remain on the lookout for promising assets to license, which bodes well for licensing prospects for PXS' LOXL-2 inhibitors. PXS also has two marketed respiratory products Bronchitol and Aridol which we view as non-core, however they represent an existing albeit small revenue stream for PXS with potential upside should US approval come through.

### INVESTMENT STRATEGY

We have a Buy (speculative) recommendation on Pharmaxis. Our investment thesis is based on:

**\$0.57 valuation:** We value PXS using a risk adjusted DCF at \$0.57. The valuation is approximately a 192.3% premium to the previous closing share price of \$0.195/sh.

**Lead assets targeting NASH have blockbuster potential:** Pharmaxis' lead assets Phase 2 SSAO/VAP-1 inhibitor BI\_1467335 and Phase 1 LOXL-2 inhibitor are both targeting Non-alcoholic Steatohepatitis (NASH), a multibillion dollar market, estimated to grow to be ~US\$20bn-US\$35bn. We model US\$1.96bn peak worldwide sales (pre risk adjustment) for BI\_1467335 in NASH and US\$1.45bn for LOXL-2 in NASH.

**NASH represents significant commercial opportunity:** NASH is a large market, growing rapidly with an increasing obese population. It is estimated that NASH will surpass Hepatitis C Virus (HCV) as the leading cause of liver transplants by 2020. There are currently no drugs approved for NASH, which makes this market largely untapped and underserved and a lucrative market opportunity for PXS to target. There are several drugs in development and interest and competition has both heated up. There have been a number of high value deals in this space recently and active companies are looking to license or acquire to build a portfolio of assets targeting different stages of NASH. Average deal sizes are around US\$860m, however some deals recently have been over \$1bn.

**PXS emerging as a key player in NASH:** Drugs targeting NASH in development fall under 3 groups based on their mechanism of action and stage of NASH they target – metabolic modifiers, anti-inflammatory agents and anti-fibrotic agents. It is expected that the future treatment for NASH is likely to be a cocktail of therapies as was seen earlier with HCV. Therefore we see drugs from each of the 3 categories to complement each other and competition likely to be restricted to drugs within the same category. Pharmaxis has two assets which fall under two different categories. BI\_1467335 is an anti-inflammatory agent and LOXL-2 asset is an anti-fibrotic agent and therefore should complement each other and other drugs in advanced development. There are very few drugs in development in these 2 categories and as far as we are aware both these drugs are currently the only one in their class being actively developed for NASH.

**Drugs not first-in-class but potentially best-in-class:** PXS' SSAO/VAP-1 and LOXL-2 inhibitor are not the first in their class. However based on pre-clinical data for both and Phase 1 data for the SSAO drug, we believe the drugs possess a more favourable PK/PD

profile which could make them best-in-class. Data so far provides evidence of good safety profile, good oral bioavailability and potent, long lasting inhibition of targeted enzyme.

**Potential exists to expand the use of lead drugs beyond NASH:** Both the lead drugs have potential to be used across fibrotic diseases with the SSAO inhibitor in a phase 2 trial for Diabetic Retinopathy (DR) and LOXL-2 being explored in Pulmonary Fibrosis.

**Partnership with Boehringer Ingelheim validates chemistry platform:** PXS signed a multi-million dollar product acquisition deal with Boehringer Ingelheim (BI) in 2015, which marked the start of the turnaround for the company, strengthened its balance sheet and validated its amine oxidase chemistry platform and its ability to execute valuable deals.

**Value inflexion points approaching:** Results from phase 2A trials for the SSAO/VAP-1 drug partnered with BI in NASH is expected in 4QCY19 and in Diabetic Retinopathy in 1HCY20. LOXL-2 has successfully completed Phase 1 trials and longer term toxicology studies and PXS is now in discussions to potentially partner it, with conclusion of the partnering process expected before end of CY19.

**Strong cash position:** PXS' current cash reserves of A\$31.1m (along with A\$6m in R&D tax rebate expected in 2HCY19) in our view, provides ~22 months cash runway, with flexibility to defer some expenses on other pipeline programs to further extend this runway. The company has a modest debt (related to finance lease) of A\$7.2m. PXS is unlikely to require any capital raisings in the medium term, given it has recently raised capital and strengthened its balance sheet. We believe the company is well placed to look at capital management initiatives such as a share buyback or special dividend to return some surplus capital to its shareholders after they finalise a deal for LOXL-2 later this year and receive a US\$10m milestone from Chiesi for Bronchitol in 2QCY20. PXS' strong cash position should also help its ongoing negotiations for the LOXL-2 asset. It will also allow it to pursue some asset acquisitions to further enrich its drug development pipeline and also allow the company to consider Phase 2A/2B development for some of its pipeline assets to add more value before partnering them out.



# Risks

The key risks specific to Pharmaxis include, but are not limited to, the following:

- **Clinical risk:** There is a risk that PXS' clinical trials for its pipeline assets fail to reach their endpoints, which would in turn impact its commercial and partnering prospects.
- **Timing and clinical risk on partnered product:** For its partnered product BI\_1467335, PXS is reliant on Boehringer Ingelheim (BI) for development timelines. The ability of PXS' product to finally reach the market and translate into royalty revenue streams for it depends on BI. Delays in timelines will affect near term milestone payments to PXS as well as its long-term revenue flow. Also if the product fails at any stage of clinical development or BI decides to discontinue the development of the product PXS' ability to generate revenue from that asset will diminish/or fail totally.
- **Reliance on partnerships to unlock value:** The success of PXS' business model is underpinned by its ability to ultimately attract valuable partnering deals for its assets, given PXS lacks the commercial infrastructure to support commercialisation. Our valuation in part is underpinned by PXS' ability to ultimately attract a valuable partnering deal for its LOXL-2 asset. Failure to attract partners for this asset or to negotiate attractive deal terms as we have postulated will impact our forecasts.
- **Bronchitol US approval decision will now affect our valuation:** While we look at Bronchitol and Aridol, PXS' currently marketed products as non-core assets and attribute minimal value to it, our inclusion of Bronchitol's US opportunity now makes our valuation vulnerable to FDA's decision on Bronchitol. FDA has issued a CRL detailing matters which Chiesi still need to address prior to approval. Key matters pertain to revisions to packaging and user instructions and running a Human Factor Study after these to test their effectiveness in enabling healthcare professionals to properly conduct a mannitol tolerance test (MTT). PXS expect approval in 1QCY20. We currently assign an 85% probability of success to US sales of Bronchitol and risk adjust the potential US\$10m milestone receivable from Chiesi on launch.
- **Regulatory risk:** Successful commercialisation of PXS' products is ultimately dependent on getting approval from the regulatory authorities to commercially launch the product. While PXS' partner with much more experience in navigating regulatory channels will be responsible for obtaining approvals, failure to satisfy regulatory requirements could mean that the product will fail to reach the market.
- **Commercial risk:** The pharmaceutical market is intensely competitive and in particular the NASH space which PXS is targeting has several companies engaged in drug development. PXS' products are unlikely to be the first to market and therefore would not have first mover advantage. There is no guarantee that mid-late stage clinical trial results of the BI drug or the LOXL-2 drug, even if they hit the endpoints of the studies, will be viewed as clinically meaningful by clinicians' vis-à-vis other approved NASH drugs by then on the market. Even if the drugs do get approved on successful pivotal studies, commercial adoption might still be hampered by the cost of the combination (especially in LOXL-2's case where we assume an add-on therapy positioning) or the competition in the NASH market having much larger impact than we have postulated.
- **Funding risk:** Delays in partnering of LOXL-2 may impact PXS' funding position in the long term. PXS has A\$31.1m in cash and debt related to finance lease of A\$7.2m. A\$6m R&D tax rebate is expected in 2HCY19. Although PXS has a high cash balance currently, which should provide ~22 months cash runway, the company may need to raise additional capital for funding its requirements beyond that should there be delays in partnering its LOXL-2 asset or in receiving the milestone from Chiesi. There is no guarantee that PXS will be able to secure additional financing if and when required.



**Table 6 - Financial summary**

Pharmaxis Ltd (PXS)						Share price (A\$)	\$0.195				
As at 16 August 2019						Market cap (A\$m)	76.9				
<b>Profit and Loss</b>						<b>Valuation data</b>					
<b>Y/e June 30 (A\$m)</b>	<b>2018A</b>	<b>2019A</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>	<b>Y/e June 30</b>	<b>2018A</b>	<b>2019A</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
Product Sales Revenues	6.1	5.7	7.0	10.5	12.6	Net profit -normalised (A\$m)	7.6	-19.0	4.0	-7.5	-9.1
Other Revenue (commercial)	43.5	0.0	24.4	9.1	0.0	EPS - normalised (c)	2.4	-4.8	1.0	-1.9	-2.3
Other Income	0.7	6.5	0.5	0.5	3.5	EPS growth (%)	NM	N/A	NM	N/A	N/A
<b>Total Revenue</b>	<b>50.2</b>	<b>12.2</b>	<b>32.0</b>	<b>20.1</b>	<b>16.1</b>	P/E ratio (x)	8.2	N/A	19.5	N/A	N/A
<b>EBITDA</b>	<b>11.5</b>	<b>-15.7</b>	<b>5.6</b>	<b>-6.2</b>	<b>-7.7</b>	FCFPS (c)	3.5	-5.3	2.9	-1.6	-2.8
Depreciation & Amortisation	-3.1	-2.6	-2.3	-2.1	-1.9	Price/FCF (x)	5.5	-3.7	6.7	-12.0	-6.9
<b>EBIT</b>	<b>8.4</b>	<b>-18.3</b>	<b>3.3</b>	<b>-8.3</b>	<b>-9.6</b>	DPS (c)	0.0	0.0	0.0	0.0	0.0
Net interest & Other Income/(Expense)	-0.8	-0.7	0.6	0.7	0.5	Yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%
<b>Pre-tax profit</b>	<b>7.6</b>	<b>-19.0</b>	<b>4.0</b>	<b>-7.5</b>	<b>-9.1</b>	Franking (%)	N/A	N/A	N/A	N/A	N/A
Tax	0.0	0.0	0.0	0.0	0.0	EV/EBITDA	4.6	-3.4	9.5	-8.5	-6.9
<b>Net profit (loss) normalised</b>	<b>7.6</b>	<b>-19.0</b>	<b>4.0</b>	<b>-7.5</b>	<b>-9.1</b>	EV/EBIT	6.3	-2.9	15.9	-6.4	-5.5
Abnormal items	-1.2	-1.1	-1.2	-1.3	-1.4						
<b>Reported Net profit (loss)</b>	<b>6.4</b>	<b>-20.1</b>	<b>2.8</b>	<b>-8.8</b>	<b>-10.4</b>						
<b>Cashflow</b>						<b>Share price now (A\$)</b> \$0.195					
<b>Y/e June 30 (A\$m)</b>	<b>2018A</b>	<b>2019A</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>	<b>Valuation (A\$):</b>	\$0.57				
Reported NPAT	6.4	-20.1	2.8	-8.8	-10.4	Premium (discount) to price	192.3%				
Non-cash items	5.6	5.6	3.8	3.7	3.5	<b>Recommendation:</b>	Buy				
Net change in Working capital	0.1	-5.4	6.0	-0.1	-3.1	<b>Risk Rating</b>	Speculative				
<b>Operating cashflow</b>	<b>12.2</b>	<b>-19.8</b>	<b>12.6</b>	<b>-5.2</b>	<b>-10.0</b>	<b>Profitability ratios</b>					
Capex	-0.8	-0.6	-0.8	-0.8	-0.8	<b>Y/e June 30</b>	<b>2018A</b>	<b>2019A</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
Investments	0.0	0.0	0.0	0.0	0.0	EBITDA margin (%)	22.9%	N/A	17.4%	N/A	N/A
Investments in intangible assets	0.0	-0.4	-0.4	-0.4	-0.4	EBIT margin (%)	16.7%	N/A	10.4%	N/A	N/A
Other investing cash flow	0.0	0.0	0.0	0.0	0.0	Return on assets (%)	15.2%	-36.0%	7.2%	-16.8%	-27.1%
<b>Investing cashflow</b>	<b>-0.9</b>	<b>-1.0</b>	<b>-1.2</b>	<b>-1.2</b>	<b>-1.2</b>	Return on equity (%)	68.5%	NM	21.1%	NM	NM
Change in borrowings	-1.5	-1.6	-1.7	-1.7	-1.8	Dividend cover (x)	N/A	N/A	N/A	N/A	N/A
Equity issued	0.0	22.7	0.0	0.0	0.0	Effective tax rate (%)	0.0%	0.0%	0.0%	0.0%	0.0%
Dividends paid	0.0	0.0	0.0	0.0	0.0	<b>Liquidity and leverage ratios</b>					
Other financing cash flow	-0.2	-0.3	-0.4	-0.8	-0.8	<b>Y/e June 30</b>	<b>2018A</b>	<b>2019A</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
<b>Financing cashflow</b>	<b>-1.8</b>	<b>20.8</b>	<b>-2.1</b>	<b>-2.5</b>	<b>-2.5</b>	Net debt (cash) (A\$m)	-22.8	-24.0	-34.5	-27.0	-14.7
<b>Net change in cash</b>	<b>9.6</b>	<b>0.1</b>	<b>9.3</b>	<b>-9.0</b>	<b>-13.8</b>	<b>Net debt/equity (%)</b>	N/A	N/A	N/A	N/A	N/A
<b>Cash at end of period*</b>	<b>31.1</b>	<b>31.1</b>	<b>40.5</b>	<b>31.5</b>	<b>17.7</b>	Net interest cover (x)	NM	N/A	NM	N/A	N/A
* Includes effect of exchange rate fluctuations on cash balance						Current ratio (x)	4.4	5.0	5.2	4.0	2.7
<b>Free cash flow</b> (op. CF less capex and intangibles)	<b>11.3</b>	<b>-20.8</b>	<b>11.4</b>	<b>-6.4</b>	<b>-11.2</b>	<b>Segmentals</b>					
<b>Balance sheet</b>						<b>Y/e June 30</b>	<b>2018A</b>	<b>2019A</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>
<b>Y/e June 30 (A\$m)</b>	<b>2018A</b>	<b>2019A</b>	<b>2020E</b>	<b>2021E</b>	<b>2022E</b>	<b>Bronchitol and Aridol</b>					
Cash	31.1	31.1	40.5	31.5	17.7	Product Sales	6.1	5.7	7.0	10.5	12.6
Current receivables	2.4	7.2	1.3	1.4	4.5	Other revenue (Clinical trial cost reimbursement)	1.3	0.0	11.3	0.0	0.0
Inventories	2.4	2.1	2.2	2.3	2.4	Other income	0.0	0.0	0.0	0.0	0.0
Other current assets	0.1	0.1	0.1	0.1	0.1	<b>Total Revenues</b>	<b>7.5</b>	<b>5.7</b>	<b>18.4</b>	<b>10.5</b>	<b>12.6</b>
<b>Current assets</b>	<b>36.0</b>	<b>40.6</b>	<b>44.1</b>	<b>35.4</b>	<b>24.8</b>	<b>EBITDA</b>	<b>-3.8</b>	<b>-5.0</b>	<b>6.2</b>	<b>-1.8</b>	<b>0.0</b>
PPE	12.5	10.3	8.6	7.2	5.9	<b>New Drug Development</b>					
Non-current receivables	1.2	1.1	1.1	1.1	1.1	Product Sales	0.0	0.0	0.0	0.0	0.0
Intangible assets	0.4	0.8	1.1	1.4	1.7	Other revenue (Milestone+license+royalty)	42.1	0.0	13.0	9.1	0.0
Other non-current assets	0.0	0.0	0.0	0.0	0.0	Other income (R&D tax incentive etc. )	0.2	6.0	0.0	0.0	3.0
<b>Non-current assets</b>	<b>14.1</b>	<b>12.1</b>	<b>10.8</b>	<b>9.6</b>	<b>8.7</b>	<b>Total Revenues</b>	<b>42.3</b>	<b>6.0</b>	<b>13.0</b>	<b>9.1</b>	<b>3.0</b>
<b>Total assets</b>	<b>50.1</b>	<b>52.7</b>	<b>54.9</b>	<b>45.0</b>	<b>33.5</b>	<b>EBITDA</b>	<b>28.8</b>	<b>-6.8</b>	<b>3.3</b>	<b>-0.5</b>	<b>-3.7</b>
Payables	5.6	4.8	4.9	4.9	4.9	<b>Corporate</b>					
Debt	8.3	7.2	5.9	4.5	3.0	Other income	0.5	0.5	0.5	0.5	0.5
Provisions	1.0	1.1	1.2	1.3	1.4	<b>EBITDA</b>	<b>-13.5</b>	<b>-3.9</b>	<b>-3.9</b>	<b>-3.9</b>	<b>-3.9</b>
Financial liabilities (Novaquest financing agreement)	22.8	23.6	23.2	22.4	21.6	<b>Total Company</b>					
Deferred Lease Incentive	1.4	1.1	0.9	0.7	0.4	Revenues	50.2	12.2	32.0	20.1	16.1
Other liabilities	0.0	0.0	0.0	0.0	0.0	<b>EBITDA</b>	<b>11.5</b>	<b>-15.7</b>	<b>5.6</b>	<b>-6.2</b>	<b>-7.7</b>
<b>Total liabilities</b>	<b>39.0</b>	<b>37.9</b>	<b>36.2</b>	<b>33.8</b>	<b>31.3</b>	<b>Interims</b>					
<b>Net Assets</b>	<b>11.1</b>	<b>14.8</b>	<b>18.8</b>	<b>11.2</b>	<b>2.1</b>	<b>Y/e June 30 (A\$m)</b>	<b>2H18A</b>	<b>1H19A</b>	<b>2H19A</b>	<b>1H20E</b>	<b>2H20E</b>
Shareholders' equity	344.6	367.3	367.3	367.3	367.3	Revenue	19.1	2.5	9.7	16.2	15.7
Reserves	20.7	21.8	22.9	24.2	25.6	<b>EBITDA</b>	3.7	-9.8	-5.8	4.0	1.5
Retained earnings/(losses)	-354.2	-374.2	-371.5	-380.3	-390.7	Depreciation & Amortisation	-1.5	-1.3	-1.3	-1.3	-0.9
<b>Total shareholders equity</b>	<b>11.1</b>	<b>14.8</b>	<b>18.8</b>	<b>11.2</b>	<b>2.1</b>	<b>EBIT</b>	<b>2.2</b>	<b>-11.1</b>	<b>-7.2</b>	<b>2.7</b>	<b>0.6</b>
						Net interest & Other Expense	-1.1	-0.8	0.1	0.2	0.4
						Pre-tax profit	1.1	-11.9	-7.1	2.9	1.0
						Tax	0.0	0.0	0.0	0.0	0.0
						<b>Net Profit (loss) - normalised</b>	<b>1.1</b>	<b>-11.9</b>	<b>-7.1</b>	<b>2.9</b>	<b>1.0</b>
						Net Profit (loss) - reported	0.5	-12.6	-7.5	2.4	0.4

SOURCE: BELL POTTER SECURITIES ESTIMATES

**Recommendation structure**

**Buy:** Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

**Hold:** Expect total return between -5% and 15% on a 12 month view

**Sell:** Expect <-5% total return on a 12 month view

*Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.*

*Such investments may carry an exceptionally high level of capital risk and volatility of returns.*

**Research Team**

Staff Member	Title/Sector	Phone	@bellpotter.com.au
TS Lim	Head of Research	612 8224 2810	tslim
<b>Industrials</b>			
Steven Anastasiou	Industrials	613 9235 1952	sanastasiou
James Filius	Industrials	613 9235 1612	jfilius
Sam Haddad	Industrials	612 8224 2819	shaddad
Alex McLean	Industrials	612 8224 2886	amclean
Hamish Murray	Industrials	613 9235 1813	hmurray
Chris Savage	Industrials	612 8224 2835	csavage
Jonathan Snape	Industrials	613 9235 1601	jsnape
Damien Williamson	Industrials	613 9235 1958	dwilliamson
<b>Healthcare/Biotech</b>			
John Hester	Healthcare	612 8224 2871	jhester
Tanushree Jain	Healthcare/Biotech	612 8224 2849	tnjain
<b>Financials</b>			
TS Lim	Banks/Regionals	612 8224 2810	tslim
Lafitani Sotiriou	Diversified Financials/Fintech	613 9235 1668	lsotiriou
<b>Resources</b>			
Peter Arden	Resources	613 9235 1833	parden
David Coates	Resources	612 8224 2887	dcoates
Stuart Howe	Resources	613 9235 1856	showe
<b>Associate</b>			
Joseph House	Associate Analyst	+61 3 9235 1624	jhouse

**Bell Potter Securities Limited**  
 ABN 25 006 390 7721  
 Level 29, 101 Collins Street  
 Melbourne, Victoria, 3000  
 Telephone +61 3 9256 8700  
 www.bellpotter.com.au

**Bell Potter Securities (HK) Limited**  
 Room 1701, 17/F  
 Prosperity Tower, 39 Queens Road  
 Central, Hong Kong, 0000  
 Telephone +852 3750 8400

**Bell Potter Securities (US) LLC**  
 Floor 39  
 444 Madison Avenue, New York  
 NY 10022, U.S.A  
 Telephone +1 917 819 1410

**Bell Potter Securities (UK) Limited**  
 16 Berkeley Street  
 London, England  
 W1J 8DZ, United Kingdom  
 Telephone +44 7734 2929

**The following may affect your legal rights. Important Disclaimer:**

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. **In Hong Kong**, this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. **In the United States**, this research is issued and distributed by Bell Potter Securities (US) LLC which is a registered broker-dealer and member of FINRA. Any person receiving this report from Bell Potter Securities (US) LLC and wishing to transact in any security described herein should do so with Bell Potter Securities (US) LLC. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

**Research Policies:** For Bell Potter's Research Coverage Decision Making Process and Research Independence Policy, please refer to our company website:

<https://www.bellpotter.com.au/topnavigation/private-clients/stockbroking/research>

**Disclosure of interest:** Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

**Disclosure:** Bell Potter Securities acted as joint lead manager for the \$24m placement in August 2018 and received fees for that service.

**Biotechnology Risk Warning:**

The stocks of biotechnology companies without strong revenue streams from product sales or ongoing service revenue should always be regarded as speculative in character. The fact that the intellectual property base of a typical biotechnology company lies in science not generally regarded as accessible to the layman adds further to the riskiness with which biotechnology investments ought to be regarded. Clinical and regulatory risks are inherent in biotechnology stocks. Biotechnology developers usually seek US FDA approval for their technology which is a long and arduous three phase process to prove the safety, effectiveness and appropriate application or use of the developed drug and even after approval a drug can be the subject of an FDA investigation of subsequently discovered possible links between the drug and other diseases not previously diagnosed. Furthermore, the Australian exchange listed biotechnology sector is subject to influence by the global biotechnology sector, particularly that in the USA. Consequently, Australian exchange listed biotechnology stocks can experience sharp movements, both upwards and downwards, in both valuations and share prices, as a result of a re-rating of the sector both globally and in the USA, in particular. Investors are advised to be cognisant of these risks before buying such a stock including **Pharmaxis Ltd. For a list of risks specific to Pharmaxis please refer to Page 8 of this note.**

**ANALYST CERTIFICATION:** Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.